[COVID-19 vaccine safety]

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• The COVID-19 pandemic necessitated rapid vaccine development, offering hope for disease control.
• Ensuring vaccine safety is paramount, requiring rigorous monitoring of adverse events following immunization (AEFIs).
• All vaccines, including those targeting SARS-CoV-2, must meet stringent safety standards for human use.

Purpose of the Study:

• To review and summarize reported adverse events associated with COVID-19 vaccines.
• To identify potential safety concerns and areas for further investigation.
• To inform ongoing vaccine safety surveillance efforts.

Main Methods:

• A literature search was conducted using the PubMed/Medline database.
• The search covered the period from August 2020 to November 2021.
• Information on adverse events from clinical trials and follow-up studies was collected.

Main Results:

• Most adverse events reported in COVID-19 vaccine clinical trials were mild to moderate in severity.
• Follow-up studies identified thrombotic events as a potential adverse event associated with certain viral vector-based COVID-19 vaccines.
• Ongoing studies and post-marketing surveillance are essential for a comprehensive understanding of vaccine safety.

Conclusions:

• COVID-19 vaccines have demonstrated an overall favorable safety profile, with most adverse events being transient and mild.
• Rare but serious adverse events, such as thrombotic events with viral vector vaccines, warrant continued monitoring and investigation.
• Comprehensive post-marketing surveillance is critical for identifying all potential adverse events and ensuring long-term vaccine safety.